#1 Clinical Trials Search in Europe

Lutetium (177Lu) Zadavotide Guraxetan

This article explores recent clinical trials investigating the use of Lutetium (177Lu) Zadavotide Guraxetan, a radioactive drug, in treating various types of cancer. The trials focus primarily on prostate cancer, but also include studies on glioma. These studies aim to evaluate the safety, efficacy, and potential benefits of this innovative treatment approach for patients with advanced or recurrent cancers.

Table of Contents

What is LUTETIUM (177LU) ZADAVOTIDE GURAXETAN?

LUTETIUM (177LU) ZADAVOTIDE GURAXETAN, also known as 177Lu-PSMA-I&T or [177Lu]Lu-PSMA-I&T, is an innovative radiopharmaceutical drug being studied for the treatment of various forms of cancer, primarily advanced prostate cancer[1]. It belongs to a class of treatments called radioligand therapy, which combines a radioactive substance (in this case, lutetium-177) with a molecule that targets specific cancer cells.

How Does It Work?

This drug works by targeting a protein called Prostate-Specific Membrane Antigen (PSMA), which is often overexpressed in prostate cancer cells. The drug binds to PSMA on the surface of cancer cells and delivers a localized dose of radiation, potentially killing the cancer cells while minimizing damage to surrounding healthy tissue[2].

What Conditions Does It Treat?

LUTETIUM (177LU) ZADAVOTIDE GURAXETAN is primarily being studied for the treatment of:

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): This is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy[1].
  • Oligoprogressive metastatic castration-refractory prostate cancer: A condition where the cancer has limited progression despite hormone therapy[4].
  • Recurrent grade 3 and grade 4 glioma: A type of brain tumor that has returned after initial treatment[3].
  • Biochemical recurrence of prostate cancer: When prostate-specific antigen (PSA) levels rise after initial curative treatment, indicating possible cancer recurrence[5].

How Is It Administered?

LUTETIUM (177LU) ZADAVOTIDE GURAXETAN is typically administered as an intravenous infusion. The treatment is usually given in cycles, with each cycle lasting about 6-8 weeks. The exact dosage and number of cycles can vary depending on the specific condition being treated and the patient’s individual characteristics[1][4].

Efficacy

While research is ongoing, early studies have shown promising results:

  • In patients with metastatic castration-resistant prostate cancer, the drug has shown potential to improve radiographic progression-free survival and overall survival compared to standard hormone therapy[1].
  • For patients with biochemical recurrence of prostate cancer, the treatment aims to achieve a significant reduction in PSA levels, potentially delaying the need for more aggressive therapies[5].
  • In recurrent glioma, researchers are exploring its potential to offer a new treatment option for patients with limited alternatives[3].

Safety and Side Effects

As with any medical treatment, LUTETIUM (177LU) ZADAVOTIDE GURAXETAN can cause side effects. Common side effects may include:

  • Myelosuppression: A decrease in blood cell production, which can lead to anemia, increased risk of infection, or bleeding[1].
  • Xerostomia: Dry mouth, which can be a result of the radiation affecting the salivary glands[4].
  • Fatigue
  • Nausea
Patients are closely monitored during treatment, and dosages may be adjusted based on individual tolerance and response[5].

Ongoing Research

Several clinical trials are currently underway to further evaluate the safety and efficacy of LUTETIUM (177LU) ZADAVOTIDE GURAXETAN:

  • A phase III trial comparing it to hormone therapy in patients with metastatic castration-resistant prostate cancer[1].
  • A study exploring its use in combination with another radiopharmaceutical, Radium-223, for bone-metastatic prostate cancer[4].
  • A phase II pilot study investigating its potential in treating biochemical recurrence of prostate cancer after initial curative treatment[5].
These ongoing studies aim to better understand the drug’s efficacy, optimal dosing, and potential applications in different stages of prostate cancer and other conditions.

Conclusion

LUTETIUM (177LU) ZADAVOTIDE GURAXETAN represents a promising advancement in the treatment of advanced prostate cancer and potentially other conditions. By targeting cancer cells more precisely, it offers hope for improved outcomes and quality of life for patients with limited treatment options. As research continues, we may see this innovative therapy become an important tool in the fight against cancer.

Trial Focus Key Objectives Patient Population Treatment Approach
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Assess improvement in radiographic progression-free survival and overall survival Men with mCRPC [177Lu]Lu-PSMA-I&T vs. hormone therapy
Oligoprogressive Metastatic Castration-Resistant Prostate Cancer Evaluate impact of metastasis-directed therapy on overall survival Patients with up to 5 progressive lesions [177Lu]Lu-PSMA-I&T alternated with Radium-223
Recurrent Grade 3 and Grade 4 Glioma Assess safety, tolerability, and efficacy Patients with recurrent high-grade glioma [177Lu]Lu-PSMA-I&T
Biochemical Recurrence of Prostate Cancer Evaluate PSA response and therapy toxicity Patients with biochemical recurrence after curative treatment [177Lu]Lu-PSMA-I&T radioligand therapy

FAQ

  • What is Lutetium (177Lu) Zadavotide Guraxetan? Lutetium (177Lu) Zadavotide Guraxetan is a radioactive drug used in targeted cancer therapy. It combines a radioactive isotope (Lutetium-177) with a molecule that targets specific proteins on cancer cells, allowing for precise delivery of radiation to tumors.
  • What types of cancer are being studied with this drug? The clinical trials are primarily focused on prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). There is also a study investigating its use in recurrent grade 3 and grade 4 glioma, a type of brain cancer.
  • How is the drug administered to patients? Lutetium (177Lu) Zadavotide Guraxetan is typically administered through intravenous infusion. The dosage and frequency of administration vary depending on the specific trial protocol.
  • What are the potential benefits of this treatment? The treatment aims to improve overall survival, delay disease progression, and enhance quality of life for patients with advanced cancers. It may offer a new option for patients who have limited treatment alternatives or have not responded well to other therapies.
  • Are there any side effects associated with this treatment? Potential side effects may include myelosuppression (decreased blood cell production), xerostomia (dry mouth), and effects on kidney function. The trials are closely monitoring patients for these and other possible adverse effects to ensure safety.

Ongoing Clinical Trials on Lutetium (177Lu) Zadavotide Guraxetan

  • Study of [177Lu]Lu-PSMA-I&T Therapy for Patients with Oligometastatic Prostate Cancer Using Gozetotide and Stannous Oxide Combination

    Recruiting

    2 1 1 1
    Investigated drugs:
    Austria

  • Study on Lutetium (177Lu) Zadavotide Guraxetan for Prostate Cancer Patients with Biochemical Recurrence After Initial Curative Treatment

    Recruiting

    2 1 1 1
    Investigated drugs:
    Austria

  • Study on the Effect of Metastasis-Directed Therapy with Lutetium (177Lu) Zadavotide Guraxetan in Patients with Advanced Prostate Cancer and Up to 5 Progressive Lesions

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Lutetium (177Lu) Zadavotide Guraxetan for Patients with Recurrent Grade 3 and Grade 4 Glioma

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on the Safety of Lutetium (177Lu) Zadavotide Guraxetan and Radium Ra 223 Dichloride for Patients with Bone-Metastatic Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study Comparing [177Lu]LU-PSMA-I&T and Hormone Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

Glossary

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): A type of advanced prostate cancer that has spread to other parts of the body and continues to grow despite treatments that lower testosterone levels.
  • Radioligand Therapy: A type of cancer treatment that uses a radioactive substance attached to a molecule that targets specific features of cancer cells.
  • PSMA (Prostate-Specific Membrane Antigen): A protein found on the surface of prostate cancer cells, which is targeted by certain cancer treatments.
  • Oligoprogressive Disease: A condition where cancer progression is limited to a small number of sites or lesions, while the rest of the disease remains stable.
  • Radiographic Progression-Free Survival (rPFS): The length of time during and after treatment that a patient lives without their cancer progressing, as determined by imaging scans.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • PSA (Prostate-Specific Antigen): A protein produced by the prostate gland; elevated levels in the blood can indicate prostate cancer or other prostate conditions.
  • Glioma: A type of tumor that occurs in the brain and spinal cord, arising from glial cells.
  • Xerostomia: Dry mouth resulting from reduced or absent saliva flow, which can be a side effect of some cancer treatments.
  • Myelosuppression: A decrease in the production of blood cells by the bone marrow, which can be a side effect of some cancer treatments.

References

  1. http://clinicaltrials.eu/trial/study-comparing-177lulu-psma-it-and-hormone-therapy-for-patients-with-metastatic-castration-resistant-prostate-cancer/
  2. http://clinicaltrials.eu/trial/study-on-the-effect-of-metastasis-directed-therapy-with-lutetium-177lu-zadavotide-guraxetan-in-patients-with-advanced-prostate-cancer-and-up-to-5-progressive-lesions/
  3. http://clinicaltrials.eu/trial/study-on-lutetium-177lu-zadavotide-guraxetan-for-patients-with-recurrent-grade-3-and-grade-4-glioma/
  4. http://clinicaltrials.eu/trial/study-on-the-safety-of-lutetium-177lu-zadavotide-guraxetan-and-radium-ra-223-dichloride-for-patients-with-bone-metastatic-prostate-cancer/
  5. http://clinicaltrials.eu/trial/study-on-lutetium-177lu-zadavotide-guraxetan-for-prostate-cancer-patients-with-biochemical-recurrence-after-initial-curative-treatment/